News in brief - January 2015 (updated)

Other new launches, licence changes and updates relevant to general practice.

The cobicistat component of Rezolsta boosts levels of darunavir in the blood and does not require concomitant ritonavir, potentially reducing the pill burden
The cobicistat component of Rezolsta boosts levels of darunavir in the blood and does not require concomitant ritonavir, potentially reducing the pill burden
  • Victoza (liraglutide) can now be used in diabetic patients with moderate renal impairment (CrCl 30–59ml/min). 
  • Eplerenone tablets (25mg and 50mg) are now available as a generic for the treatment of patients with LVEF ≤40% and clinical evidence of heart failure after MI, and those with chronic heart failure and LVEF ≤30%.
  • Janssen has launched Rezolsta, a fixed-dose combination tablet containing the protease inhibitor darunavir and the pharmacoenhancer cobicistat, for the treatment of HIV infection.
  • Aripiprazole tablets are now available as a generic for the treatment of schizophrenia in adults.
  • The oral androgen receptor antagonist Xtandi (enzalutamide) is now licensed for metastatic castration-resistant prostate cancer in men who are asymptomatic or mildly symptomatic and in whom chemotherapy is not yet indicated.

Follow MIMS on Twitter

Sign up for MIMS bulletins

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more